Risperdal Lawsuit News: Bernstein Liebhard LLP Notes Publication of New Study Linking Risperidone to Development of Gynecomastia in Men

News provided by

Oct 24, 2014, 01:13 ET

NEW YORK, Oct. 24, 2014 /PRNewswire/ -- As Risperdal lawsuits (www.risperdallawsuit2014.com) involving gynecomastia, or male breast growth, continue to move forward in U.S. courts, Bernstein Liebhard LLP notes the publication of new research linking the use of risperidone to the development of the condition. The findings, which appear in the October 2014 issue of the Journal of Clinical Psychopharmacology, were drawn from a comparison of 8,000 men who suffered from gynecomastia, ages 40 to 85 years, with 83,000 controls in the same age group that was conducted between June 2001 and June 2011. Those who were treated with risperidone had a 69% increased risk of gynecomastia compared to men who did not take the medication. The risperidone patients also were 40% more likely to develop the condition compared to those who took other antipsychotics, like Seroquel or Zyprexa.

Risperidone is an atypical antipsychotic sold under the brand name Risperdal. The medication is approved to treat adult and adolescent schizophrenia, bipolar disorder in adults and children ages 10-to-17, and irritability in children (5-to-16 years of age) with autistic disorder.

"Our Firm is representing numerous men in Risperdal lawsuits who allegedly developed gynecomastia due to risperidone. This is just the latest research to link the disorder to the use of this atypical antipsychotic drug," says Bernstein Liebhard LLP, a nationwide law firm representing the victims of defective drugs and medical devices. The Firm is currently offering free legal consultations to men and boys who allegedly developed gynecomastia, or male breast growth, due to their use of Risperdal.

Risperdal Gynecomastia Litigation

In recent years, a growing body of research has suggested an association between the use of risperidone and gynecomastia. In 2006, for example, another study published in the Journal of Clinical Psychopharmacology reported that the medication could cause the body to produce excessive amounts of a hormone called prolactin, which is known to stimulate breast growth and milk production in women. Excessive levels of prolactin were associated with gynecomastia in boys and the development of lactation in girls, according to the study authors

Another study published in 2009 in the Journal of Child and Adolescent Psychology found that elevated prolactin levels associated with risperidone use can persist for up to two years.

Court documents indicate that more than 900 Risperdal lawsuits have been filed in a mass tort litigation now underway in Pennsylvania's Philadelphia Court of Common Pleas on behalf of individuals who allegedly suffered gynecomastia and other serious complications due to their use of the drug. Among other things, these claims accuse Johnson & Johnson and its Janssen Pharmaceuticals unit of concealing the drug's serious side effects and of failing to warn doctors and patients of these risks, including its association with male breast growth and elevated prolactin levels. Plaintiffs also allege that the companies improperly marketed Risperdal for unapproved uses, including certain pediatric indications prior to their regulatory approval. The litigation's first trial of a Risperdal case involving gynecomastia is scheduled to begin on November 3, 2014. (In Re: Risperdal Litigation, Case Number 100300296).

Men and boys who allegedly developed gynecomastia due to Risperdal may be entitled to take legal action against the manufacturers of the medication. To learn more about filing a Risperdal lawsuit, please visit Bernstein Liebhard LLP's website. For a free case review, please call (888) 340-4807.

About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993, including those who have been harmed by dangerous drugs, defective medical devices and consumer products. The firm has been named by The National Law Journal to the Plaintiffs' Hot List, recognizing the top plaintiffs firms in the country, for the past 12 consecutive years. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list every year since the list was first published in 2003.

Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
(888) 340-4807

ATTORNEY ADVERTISING. © 2014 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (888) 340-4807. Prior results do not guarantee or predict a similar outcome with

Contact Information:
Felecia L. Stern, Esq.
info (at) consumerinjurylawyers (dot) com
www.risperdallawsuit2014.com

https://plus.google.com/115936073311125306742?rel=author

Logo - http://photos.prnewswire.com/prnh/20120202/MM47134LOGO

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/risperdal-lawsuit-news-bernstein-liebhard-llp-notes-publication-of-new-study-linking-risperidone-to-development-of-gynecomastia-in-men-813387580.html

SOURCE Bernstein Liebhard LLP